Skip to main content
. Author manuscript; available in PMC: 2011 Oct 1.
Published in final edited form as: Melanoma Res. 2010 Oct;20(5):361–371. doi: 10.1097/CMR.0b013e328336ee17

Table 1.

Molecular characterization of the cell lines used in this work

B-RAF N-RAS/ C-KIT p16-CDK4-RB ARF-p53 pERK status pAKT status Orthopic growth as xenograft
A375 V600E mut. WT Undetectable p16 mRNA HD of ARF, p53 WT & funct. high low yes
A2058 V600E mut. WT Rb null Undetectable ARF mRNA, p53 funct. med high yes
SK-MEL24 V600E mut. WT HD of 9p21 HD of 9p21, p53 funct. high high no
SK-MEL28 V600E mut. WT CDK4 Arg24Cys mut. p53 Mut (Leu145Arg) high high yes
UACC257 V600E mut. WT p16 mut. Unknown ARF - p53 lesion high high no
WM2664 V600E mut. WT HD of 9p21 HD of 9p21, p53 funct. high high yes
Mel505 WT WT Undetectable p16 mRNA p53 inact. low low yes
PMWK WT WT Unknown p16 - RB lesion p53 inact. low low no
RPMI8322 WT WT Unknown p16 - RB lesion p53 inact. med low yes
SK-MEL23 WT WT n.d. n.d. n.d. n.d. no
SK-MEL187 WT WT HD of 9p21 p53 mut (Arg273His) low low yes

HD: homozygous deletion.